Eligibility for Olaparib treatment generally depends on the type of cancer and the presence of specific genetic mutations, such as BRCA1 or BRCA2. Healthcare providers often conduct genetic testing to determine whether a patient is a suitable candidate for this therapy. Patients with a strong family history of cancer may also be considered for genetic testing to assess their eligibility.
